Alcon (ALC) AI Stock Analysis

• Market Cap: $29.09B
• Dividend Yield: 0.44%
• Average Volume (3M): 1.14M
• Price to Earnings (P/E): 38.3
• Beta (1Y): 0.99
• Revenue Growth: 0.39%
• EPS Growth: -12.46%
• Country: CH
• Employees: 25,599
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.60
• Shares Outstanding: 499,700,000
• 10 Day Avg. Volume: 972,018
• 30 Day Avg. Volume: 1,144,190
• PEG Ratio: 39.50
• Price to Book (P/B): 1.79
• Price to Sales (P/S): 3.61
• P/FCF Ratio: 21.75
• Enterprise Value/Market Cap: 1.37
• Enterprise Value/Revenue: 3.82
• Enterprise Value/Gross Profit: 6.92
• Enterprise Value/Ebitda: 19.66
• 1Y Price Target: $75.62
• Price Target Upside: 29.89% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): 2.65
• Revenue Forecast (FY): $8.66B

• Rating: 72 Outperform
• Price Target: CHF65.00 ▲(11.65% Upside)
• Action: Reiterated Date: 02/28/26
• Date: Action: Reiterated 02/28/26

The score is driven primarily by solid fundamentals (steady growth, healthy profitability, improving free cash flow, and manageable leverage) and supportive technical momentum (price above major moving averages with positive MACD). These positives are tempered by an expensive valuation (high P/E with low yield) and near-term execution/margin risks noted on the earnings call, including tariff impacts and competitive pressures.

Positive Factors

Recurring revenue streams

Alcon’s dual model—capital equipment plus high-frequency consumables and contact lens replenishment—creates durable recurring revenue tied to procedure volumes and patient refill cycles. That installed-base economics supports predictable revenue, stickier customer relationships, and steadier cash generation over time.

Product pipeline & launches

A steady cadence of premium product introductions (Unity, PanOptix Pro, Truqtra/TruPlus, Total30, Valeda) enhances Alcon’s ability to capture share in higher-margin segments and refresh its installed base. Successful rapid adoption (e.g., Truqtra prescriptions) signals sustainable new revenue streams and stronger long-term mix.

Strong cash generation & returns

Robust free cash flow and disciplined capital allocation (large buybacks and dividends) demonstrate the business’s ability to convert earnings into cash. This underpins financial flexibility to invest in R&D, fund equipment rollouts, and sustain shareholder returns without relying on external financing.

Negative Factors

Tariff-related margin headwind

Sustained elevated import tariffs materially raise cost of goods sold and create structural margin pressure that management must offset with price, mix shifts, or efficiency programs. Tariff exposure is geopolitical and hard to forecast, adding durable uncertainty to gross margin sustainability and planning.

Uneven cash conversion & margin softness

Although FCF improved, operating cash flow lagging net income and a dip in net margin indicate working-capital timing and margin pressures. Inconsistent cash conversion and recent margin compression reduce earnings quality and limit free cash flow reliability until conversion stabilizes.

Intensifying IOL competition & regional softness

A more competitive premium IOL landscape and softer demand in key geographies (Japan, China, parts of Asia) constrain pricing power and adoption of higher-margin implants. Structural budget constraints and competitive share shifts can depress long-term growth and slow premiumization of the implantable installed base.

Alcon Business Overview & Revenue Model

Company Description

Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

How the Company Makes Money

Alcon makes money by selling eye care products and related services across two main revenue streams: (1) Surgical and (2) Vision Care. 1) Surgical revenue (ophthalmic surgery) - Capital equipment sales: Alcon sells large ophthalmic surgical systems to hospitals, ambulatory surgery centers, and clinics (e.g., systems used in cataract and vitreoretinal procedures). These are typically higher-priced, lower-frequency purchases. - Consumables and procedure-based product sales: A significant portion of Surgical revenue is tied to recurring demand for single-use or limited-use items used in procedures, such as intraocular lenses (IOLs), viscoelastic devices, surgical packs, fluids, blades, handpieces, and other disposables. Revenue scales with surgical procedure volumes (e.g., cataract surgery volume) and installed base utilization. - Service, maintenance, and accessories: Alcon generates additional revenue from service contracts, repairs, upgrades, and accessories associated with its installed equipment base. 2) Vision Care revenue (contact lenses and ocular health) - Contact lens sales: Alcon sells daily and reusable contact lenses, generally through eye care professionals (optometrists/ophthalmologists) and also via optical/retail and other distribution channels depending on country. Revenue is driven by patient adoption, refits, replacement frequency, and product mix. - Lens care and ocular health products: Alcon earns revenue from solutions and other eye care products used for contact lens maintenance and comfort/ocular health. These products provide recurring sales tied to ongoing consumer use. Commercial model and drivers - Channel-based distribution: Alcon sells via a mix of direct sales forces and distributors, depending on geography and product line. Surgical sales are often relationship-driven with clinical accounts, while Vision Care relies on both professional recommendation and consumer purchasing behavior. - Recurring demand characteristics: Although Alcon sells capital equipment, a meaningful economic driver is the recurring, procedure-linked consumables (Surgical) and replenishment cycle for contact lenses and care products (Vision Care). - Pricing and mix: Earnings are influenced by the mix of premium versus value products (e.g., higher-end IOLs or premium contact lens offerings), competitive dynamics, reimbursement environments in some markets, and foreign exchange given its global footprint. Partnerships or specific revenue-sharing arrangements: null

Alcon Financial Statement Overview

Summary

Steady 2023–2025 revenue growth with healthy gross margin (~55%) and improving free cash flow, supported by manageable leverage. Offsets include modest ROE (~4–5%), some 2025 margin softening versus 2024, and uneven cash conversion (operating cash flow and FCF below net income in 2025 per the provided statements).

Income Statement

Revenue has grown steadily from 2023–2025 (to ~10.9B in 2025) with positive growth in each of the last three annual periods, pointing to improving demand and execution. Profitability has strengthened materially versus 2020, with 2025 gross margin ~55% and net margin ~9%; however, net margin peaked in 2023–2024 (~10%) and dipped in 2025, and operating profitability also eased in 2025 versus 2024. Overall, solid growth and healthy margins, but with some recent margin compression to monitor.

Balance Sheet

Leverage appears manageable: debt is ~5.7B against equity of ~22.0B in 2025, keeping debt relative to equity around ~0.26 and fairly stable over time. Asset base has expanded (to ~31.5B in 2025), supporting scale and resilience. The main weakness is modest shareholder returns (return on equity ~4–5% in 2023–2025), suggesting profitability is good but not yet translating into high returns on the capital base.

Cash Flow

Cash generation improved meaningfully: free cash flow rose from ~0.54B (2023) to ~1.81B (2025), with strong 2025 growth. That said, cash conversion is not consistently strong—2025 operating cash flow is below net income (coverage ~0.78), and free cash flow is also below net income (~0.76), indicating working-capital or cash timing headwinds. Overall trending better with stronger free cash flow, but quality/consistency of conversion is a key watch item.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	10.90B	9.91B	9.46B	8.72B	8.29B
Gross Profit	6.02B	5.51B	5.25B	4.75B	4.65B
EBITDA	2.78B	2.68B	2.24B	1.72B	1.76B
Net Income	1.03B	1.02B	974.00M	335.00M	376.00M
Balance Sheet
Total Assets	31.53B	30.35B	29.61B	29.21B	28.00B
Cash, Cash Equivalents and Short-Term Investments	1.61B	1.83B	1.10B	980.00M	1.58B
Total Debt	5.67B	5.14B	5.13B	5.07B	4.48B
Total Liabilities	9.51B	8.79B	8.99B	9.53B	8.74B
Stockholders Equity	22.02B	21.55B	20.62B	19.68B	19.26B
Cash Flow
Free Cash Flow	1.81B	1.41B	537.00M	472.00M	165.00M
Operating Cash Flow	2.38B	2.08B	1.39B	1.22B	1.34B
Investing Cash Flow	-1.44B	-1.17B	-1.09B	-1.86B	-1.20B
Financing Cash Flow	-1.14B	-322.00M	-211.00M	-8.00M	-123.00M

Alcon Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 58.22
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:ALC, the sentiment is Negative. The current price of 58.22 is below the 20-day moving average (MA) of 63.06, below the 50-day MA of 62.62, and below the 200-day MA of 64.43, indicating a bearish trend. The MACD of -0.96 indicates Positive momentum. The RSI at 31.03 is Neutral, neither overbought nor oversold. The STOCH value of 2.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:ALC.

Alcon Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NOVN	78 Outperform	CHF220.01B	18.30	―	3.18%	7.62%	-18.33%
ROG	73 Outperform	CHF240.33B	20.28	31.98%	2.94%	4.77%	-11.07%
ALC	72 Outperform	$29.09B	38.35	4.44%	0.44%	0.39%	-12.46%
SOON	68 Neutral	CHF10.27B	17.11	―	2.14%	3.79%	-7.84%
STMN	66 Neutral	CHF12.09B	41.72	―	1.02%	4.49%	45.08%
GALD	63 Neutral	CHF33.37B	75.41	―	0.09%	6.22%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%